News | March 18, 2024
AstraZeneca to acquire Amolyt Pharma
Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond complement inhibition
Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond complement inhibition
It is the first autotaxin inhibitor to be investigated in cancer patients
India has reached to nearly 6,000 bio-startups from 50 in the past 10 years
The validations confirm the completion of the applications and commence the scientific review process
Survodutide has potential to become best-in-class treatment for metabolic dysfunction-associated steatohepatitis
Orchid is the first company from India, ever to have invented a product which has received a New Drug Approval (NDA) from USFDA
The acquisition will build on AstraZeneca’s expertise in respiratory syncytial virus
Through our research, we aim to ultimately provide new options for our customers to treat life-threatening infections in livestock
MASH is a chronic and progressive liver disease characterised by fat accumulation and inflammation in the liver,
Exblifeb demonstrates remarkable efficacy in treating complicated Urinary Tract Infections (cUTI), pneumonia
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
